Facharzt für Innere Medizin, Gastroenterologie sowie Hämatologie und Internistische Onkologie, Infektiologie. Qualifikation zur fachgebundenen genetischen Beratung – für Gastroenterologie sowie Hämatologie/Onkologie
Lebenslauf
Mitgliedschaften
Wissenschaftliche Schwerpunkte:
Gastrointestinale Onkologie, Pankreaskarzinom, Humanitäre Medizin
Publikationen
1: Hartlapp I, Valta-Seufzer D, Siveke JT, Algül H, Goekkurt E, Siegler G,
Martens UM, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ,
Held S, Keller R, Anger F, Germer CT, Stang A, Kimmel B, Heinemann V, Kunzmann
V; German Pancreatic Cancer Group (AIO-PAK) and NEOLAP investigators. Prognostic
and predictive value of CA 19-9 in locally advanced pancreatic cancer treated
with multiagent induction chemotherapy: results from a prospective, multicenter
phase II trial (NEOLAP-AIO-PAK-0113). ESMO Open. 2022 Aug;7(4):100552. doi:
10.1016/j.esmoop.2022.100552. Epub 2022 Aug 12. PMID: 35970013; PMCID:
PMC9434418.
2: Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt
D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein
I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V;
German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by
FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol
Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020
Dec 16. PMID: 33338442.
3: Kunzmann V, Herrmann K, Bluemel C, Kapp M, Hartlapp I, Steger U. Intensified
Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by
FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
Case Rep Oncol. 2014 Sep 18;7(3):648-55. doi: 10.1159/000367966. PMID: 25408659; PMCID: PMC4209279.
4: Hartlapp I, Müller J, Kenn W, Steger U, Isbert C, Scheurlen M, Germer CT,
Einsele H, Kunzmann V. Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy. Onkologie. 2013;36(3):123-5. doi: 10.1159/000348527. Epub 2013 Feb
25. PMID: 23486001.
5: Hartlapp I, Pallasch C, Weibert G, Kemkers A, Hummel M, Re D. Depsipeptide
induces cell death in Hodgkin lymphoma-derived cell lines. Leuk Res. 2009
Jul;33(7):929-36. doi: 10.1016/j.leukres.2008.12.013. Epub 2009 Feb 23. PMID:
19233470.
6: Re D, Hartlapp I, Greiner A, Diehl V, Wickenhauser C. Analysis of
CARMA1/BCL10/MALT1 expression in Reed-Sternberg cells of classical Hodgkin
lymphoma. Leuk Lymphoma. 2008 Feb;49(2):362-4. doi: 10.1080/10428190701784722.
PMID: 18231929.
7: Hoopmann M, Rahimi G, Hartlapp I, Eifinger F, Garnier Y, Bald R.
Chemotherapieinduzierte fetale Anämie bei akuter myeloischer Leukämie der Mutter
[Chemotherapy-induced fetal anemia in maternal acute myelocytic leukemia].
Ultraschall Med. 2008 Aug;29(4):424-7. German. doi: 10.1055/s-2007-963219. Epub
2007 Aug 23. PMID: 17717788.
8: Hartlapp I, Bühring U, Dichgans J, Isenmann S. A patient with Marfan's
syndrome and neurofibromatosis type 1 with polyneuropathy. Eur J Neurol. 2004
Sep;11(9):641-4. doi: 10.1111/j.1468-1331.2004.00913.x. PMID: 15379745.
9: Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A
recombinant bispecific single-chain antibody induces targeted, supra-agonistic
CD28-stimulation and tumor cell killing. Eur J Immunol. 2003 May;33(5):1334-40.
doi: 10.1002/eji.200323322. PMID: 12731059.
10: Hartlapp I, Abe R, Saeed RW, Peng T, Voelter W, Bucala R, Metz CN.
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and
promote angiogenesis in vivo. FASEB J. 2001 Oct;15(12):2215-24. doi:
10.1096/fj.01-0049com. PMID: 11641248.
Unternehmensbereiche
